Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Puente, A
  • Turón, F
  • Martínez, J
  • Fortea, JI
  • Guerra, MH
  • Alvarado, E
  • Pons, M
  • Magaz, M
  • Llop, E
  • Alvarez-Navascués, C
  • Navarrete, AA
  • Masnou, H
  • Bañares, R
  • Casado, M
  • Ampuero, J
  • Rios, J
  • Saavedra, C
  • Blasi, A
  • Lisman, T
  • Figuero, CR
  • Huelin, P
  • Tellez, L
  • Arráez, DM
  • Rodriguez, M
  • Loste, MTA
  • Baiges, A
  • Hernandez-Gea, V
  • Perelló, C
  • Calleja, JL
  • Genescà, J
  • Villanueva, C
  • Gonzalez-Alayón, C
  • Albillos, A
  • Crespo, J
  • Garcia-Pagán, JC

Grupos

Abstract

Background & Aims: Previous studies suggest that anticoagulation may reduce the risk of portal hypertension (PHT)-related complications and improve survival in patients with cirrhosis. This study aimed to evaluate the efficacy and safety of the direct oral anticoagulant rivaroxaban in patients with cirrhosis. Methods: This was a randomized, double-blind, placebo-controlled, multicenter trial involving patients with cirrhosis, PHT, and moderate liver dysfunction (Child-Pugh score 7-10). Participants received either rivaroxaban 10 mg daily or placebo for 24 months. The primary composite endpoint was the development of a PHT-related complication or death/liver transplantation, whichever occurred first. Analyses were conducted using both modified intention-to-treat and per-protocol approaches. Results: A total of 90 patients were enrolled (49 placebo, 41 rivaroxaban). After a median follow-up of 10.1 months, 34 patients reached the primary endpoint: 23 (46.9%) in the placebo group vs. 11 (26.8%) in the rivaroxaban group. The cumulative probability of survival free from the primary endpoint at 1 and 2 years was 54.4% and 43.0% in the placebo group, compared to 78.7% and 67.1% in the rivaroxaban group (log-rank p = 0.058). In a post hoc analysis of patients with Child-Pugh B7 scores (n = 55), rivaroxaban showed a potentially beneficial effect (hazard ratio 0.258; 95% CI 0.074-0.900). In the per-protocol analysis (41 placebo, 37 rivaroxaban), the primary event occurred in 19 patients (46.3%) in the placebo group vs. 9 (24.3%) in the rivaroxaban group (hazard ratio 0.463; 95% CI 0.209-1.024). Non-PHT-related bleeding events were more frequent in the rivaroxaban group (36.6% vs. 14.3%; relative risk 2.56; 95% CI 1.16-5.67). However, there were no significant differences in major bleeding events. Conclusions: In patients with cirrhosis and moderate liver dysfunction, rivaroxaban may improve PHT complication-free survival without significantly increasing the risk of major bleeding. ClinicalTrials.gov: NCT02643212. EudraCT Number: 2014-005523-27. (c) 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Copyright © 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0168-8278, 1600-0641

JOURNAL OF HEPATOLOGY  ELSEVIER

Tipo:
Article
Páginas:
1069-1076
PubMed:
40691992
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
7,351 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 20

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Direct oral anticoagulants; Portal hypertension

Compartir